LMDP10-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemELMDP10Cat.No.:HY-178054CASNo.:2760446-25-9分⼦式:C₂₉H₂₁FN₄O₃分⼦量:492.5作⽤靶点:Keap1-Nrf2;DrugDerivative作⽤通路:NF-κB;Others储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性LMDP10⼀种具有⼝服活性的3-氨喹唑啉衍⽣物，具有Keap1-Nrf2通路激活活性。LMDP10与Keap1结合，抑制Keap1-Nrf2相互作⽤，从⽽激活Nrf2通路。LMDP10提⾼Nrf2、SOD和GSH⽔平，降低MDA和TNF-α⽔平，减轻阿尔茨海默病(AD)⼤⿏的神经退⾏性变，并改记忆功能。LMDP10可⽤于阿尔茨海默病(AD)研究[1]。体内研究LMDP10(5-50mg/kg,p.o.,oncedaily,10days)significantlyimprovesspatialmemoryinICV-STZ-inducedsporadicAlzheimer’sdisease(AD)maleSDrats[1].AnimalModel:MaleSprague-Dawley(SD)rats(250-300g)wereusedtoestablishthesporadicAlzheimer’sdisease(AD)model[1]Dosage:5,10,50mg/kgAdministration:p.o.,oncedaily,10daysResult:Increasedtargetquadranttime.Elevateddiscriminationindex.IncreasedcorticalandhippocampalNrf2.RaisedSOD/GSHandreducedMDA.Loweredcortical/hippocampalTNF-α.Reduceddegeneratedneuronsinhippocampus/cortex.REFERENCES1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE[1].MahetaP,etal.NeuroprotectiveEffectsofa3-AminoQuinazolineDerivativeviaKeap1-Nrf2PathwayActivationinanICV-STZ-InducedRatModelofSporadicAlzheimer'sDisease.ACSChemNeurosci.2025Sep17;16(18):3611-3622.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792ax: